US asks Bharat Bio partner Ocugen to halt Covaxin trials https://ift.tt/2YxDHWN

"The company was informed by the USFDA that the agency placed its phase 2/3 immuno-bridging and broadening study for Covaxin (BBV152), OCU-002, on clinical hold," Ocugen said in a statement.

from Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/qSVOsme
Share:

No comments:

Post a Comment

Search This Blog

Powered by Blogger.

Labels

Unordered List

  • Lorem ipsum dolor sit amet, consectetuer adipiscing elit.
  • Aliquam tincidunt mauris eu risus.
  • Vestibulum auctor dapibus neque.

Pages

Theme Support

Need our help to upload or customize this blogger template? Contact me with details about the theme customization you need.